Breyanzi Approved for Relapsed or Refractory Mantle Cell Lym

The FDA has approved Breyanzi (lisocabtagene maraleucel) for the treatment of previously treated adults with relapsed or refractory mantle cell lymphoma.

Related Keywords

Houston , Texas , United States , Michael Wang , Drug Administration , University Of Texas Md Anderson Cancer Center , Transcend , Department Of Lymphoma , Division Of Cancer Medicine , Puddin Clarke Endowed Professor , Cancer Medicine , Cancer Center ,